169 related articles for article (PubMed ID: 38012196)
1. Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma.
Awuah D; Li L; Williams L; Urak R; Kujawski M; Forman SJ; Shively JE; Wang X
Sci Rep; 2023 Nov; 13(1):20853. PubMed ID: 38012196
[TBL] [Abstract][Full Text] [Related]
2. Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1
Lum LG; Thakur A; Elhakiem A; Alameer L; Dinning E; Huang M
Front Oncol; 2020; 10():544. PubMed ID: 32432032
[No Abstract] [Full Text] [Related]
3. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
[No Abstract] [Full Text] [Related]
4. A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.
Chan WK; Kang S; Youssef Y; Glankler EN; Barrett ER; Carter AM; Ahmed EH; Prasad A; Chen L; Zhang J; Benson DM; Caligiuri MA; Yu J
Cancer Immunol Res; 2018 Jul; 6(7):776-787. PubMed ID: 29769244
[TBL] [Abstract][Full Text] [Related]
5. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
Park JA; Cheung NV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086947
[TBL] [Abstract][Full Text] [Related]
6. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells.
O'Neal J; Ritchey JK; Cooper ML; Niswonger J; Sofía González L; Street E; Rettig MP; Gladney SW; Gehrs L; Abboud R; Prior JL; Haas GJ; Jayasinghe RG; Ding L; Ghobadi A; Vij R; DiPersio JF
Leukemia; 2022 Jun; 36(6):1625-1634. PubMed ID: 35422095
[TBL] [Abstract][Full Text] [Related]
7. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis.
Rosenzweig M; Urak R; Walter M; Lim L; Sanchez JF; Krishnan A; Forman S; Wang X
Cytotherapy; 2017 Jul; 19(7):861-866. PubMed ID: 28483281
[TBL] [Abstract][Full Text] [Related]
8. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
[TBL] [Abstract][Full Text] [Related]
9. Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy.
Kujawski M; Li L; Bhattacharya S; Wong P; Lee WH; Williams L; Li H; Chea J; Poku K; Bowles N; Vaidehi N; Yazaki P; Shively JE
BMC Cancer; 2019 Sep; 19(1):882. PubMed ID: 31488104
[TBL] [Abstract][Full Text] [Related]
10. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.
Chu J; He S; Deng Y; Zhang J; Peng Y; Hughes T; Yi L; Kwon CH; Wang QE; Devine SM; He X; Bai XF; Hofmeister CC; Yu J
Clin Cancer Res; 2014 Aug; 20(15):3989-4000. PubMed ID: 24677374
[TBL] [Abstract][Full Text] [Related]
11. Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.
Nakajima M; Guo HF; Hoseini SS; Suzuki M; Xu H; Cheung NV
Pediatr Blood Cancer; 2021 Jul; 68(7):e28971. PubMed ID: 33844437
[TBL] [Abstract][Full Text] [Related]
12. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
[TBL] [Abstract][Full Text] [Related]
13. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
14. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.
Bae J; Song W; Smith R; Daley J; Tai YT; Anderson KC; Munshi NC
Br J Haematol; 2012 Jun; 157(6):687-701. PubMed ID: 22533610
[TBL] [Abstract][Full Text] [Related]
15. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
Veillette A; Guo H
Crit Rev Oncol Hematol; 2013 Oct; 88(1):168-77. PubMed ID: 23731618
[TBL] [Abstract][Full Text] [Related]
16. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.
Golubovskaya V; Zhou H; Li F; Berahovich R; Sun J; Valentine M; Xu S; Harto H; Sienkiewicz J; Huang Y; Wu L
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680541
[TBL] [Abstract][Full Text] [Related]
17. [Bispecific antibodies in multiple myeloma].
Escure G; Manier S
Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
[No Abstract] [Full Text] [Related]
19. CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma.
De Veirman K; Puttemans J; Krasniqi A; Ertveldt T; Hanssens H; Romao E; Hose D; Goyvaert C; Vlummens P; Muyldermans S; Breckpot K; Bruchertseifer F; Morgenstern A; D'Huyvetter M; Devoogdt N
Oncoimmunology; 2021; 10(1):2000699. PubMed ID: 34777918
[TBL] [Abstract][Full Text] [Related]
20. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Tai YT; Dillon M; Song W; Leiba M; Li XF; Burger P; Lee AI; Podar K; Hideshima T; Rice AG; van Abbema A; Jesaitis L; Caras I; Law D; Weller E; Xie W; Richardson P; Munshi NC; Mathiot C; Avet-Loiseau H; Afar DE; Anderson KC
Blood; 2008 Aug; 112(4):1329-37. PubMed ID: 17906076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]